Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Implementation of Long Term Incentive Plan

10 Nov 2017 12:14

RNS Number : 1942W
Eland Oil & Gas PLC
10 November 2017
 

10 November 2017

 

Eland Oil & Gas PLC

 ("Eland" or the "Company")

 

Implementation of Long Term Incentive Plan

 

Eland Oil & Gas PLC (AIM: ELA), an oil and gas production and development company operating in West Africa with an initial focus on Nigeria announces that, further to the Company's remunerations report within its 2016 Annual Report and Accounts and following an extensive review, a new Long-Term Incentive Plan ("LTIP") has been adopted by the board and approved by the Remuneration Committee and has granted a total of 9,154,00 nil cost options. Conditional upon the award, the recipients have to return 3,069,438 existing share options such that the net grant amounts to 6,084,562 options.

Background and Performance Conditions

The revised LTIP has been established to incentivise Executives to deliver long-term sustainable value for Eland shareholders. The LTIP is also designed to align the interests of management with the interests of shareholders.

The structure of the awards is over a 3-year period, deemed to have commenced in July 2017, and is based upon the following criteria:

· Price: the base price below which no options will vest under this award is 50p ("Base Price")

· Total shareholder return: 60% of the award will vest on a straight-line basis depending on the volume weighted average price of an ordinary share as measured with zero vesting at the Base Price and full vesting of this proportion at 200p per share, representing a 300% increase over the Base Price. In order for this proportion of the award to be met in full, the Company will need to have delivered total shareholder return of approximately 60% compound over the 3-year vesting period.

· Oil price: 15% of the award will vest provided the numerical value of the share price expressed in pence, is greater than the numerical value of the average Brent Crude oil price over the share price Measurement Period (as defined in the share option agreement), expressed in US dollars per barrel

· Determination of the vesting for the total shareholder return and oil price criteria will be at the end of the 3-year period.

· Production: 25% of the award will be subject to the Company's gross sales barrels reaching 40,000 barrels of oil per day. The 25% will reduce in a straight line between the maximum vesting at 40,000 barrels of oil per day to nil at 25,000 barrels of oil per day. This proportion will vest on the performance criteria being met when averaged over any 3-month period during the measurement period.

· The new plan incorporates standard malus and claw back clauses and acceptance of the option requires senior executives to build and retain stock to the value of one times salary and one and a half times salary in the case of the CEO.

 

The following awards have been made to PDMRs

Director and PDMR

Number of ordinary share options of £0.10 each prior to new LTIP award

Number of previous ordinary share options of £0.10 returned

Number of ordinary shares of £0.10 each ("Shares") over which LTIP Awards were granted.

Vesting Date

Total Number of Options Held

George Maxwell (CEO)

3,324,252

 

2,123,438

2,800,000

27 July 2020

4,000,814

Ronald Bain (CFO)

-

-

1,200,000

27 July 2020

1,200,000

 

 

 

Following this award the company will have 12,292,485 shares under option representing 5.58% of shares in issued.

 

Chairman Russell Harvey commented.

The new LTIP, which has been adopted by the board, provides both challenging but achievable targets and a substantial prize for both shareholders and employees when they are achieved. It is judged fit for purpose given the company's assets and ambition and the quantum of allocation recognizes both the achievements to date and expectations for the future.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

George Maxwell

 

2

Reason for the notification

a)

Position/status

 

Chief Executive Officer

 

b)

Initial notification /Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Eland Oil & Gas Plc

b)

 

LEI

 

213800QDGQKG3JKKRR86

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Ordinary Shares £0.10 each

GB00B8HHWX64

b)

 

Nature of the transaction

 

Shares Options through Company's Share Incentive Plan

c)

 

Price(s) and volume(s)

 

 

 Call Price(s)

 

Volume(s)

10p

2,800,000

d)

 

Aggregated information

 

- Aggregated volume

 

 

- Price

 

Date 10/11/2017

2,800,000 @ 10pence

Date 31/1/2016

500,000 @ 29 pence

Date 31/8/2012

700,814 @ £1

 

e)

 

Date of the transaction

 

10 November 2017

 

f)

 

Place of the transaction

 

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Ronald Bain

 

2

Reason for the notification

a)

Position/status

 

Chief Financial Officer

 

b)

Initial notification /Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Eland Oil & Gas Plc

b)

 

LEI

 

213800QDGQKG3JKKRR86

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

a)

 

Description of the financial instrument, type of instrument

Identification code

 

Ordinary Shares £0.10 each

GB00B8HHWX64

b)

 

Nature of the transaction

 

Shares Options through Company's Share Incentive Plan

c)

 

Price(s) and volume(s)

 

 

 Call Price(s)

 

Volume(s)

10p

1,200,000

d)

 

Aggregated information

 

- Aggregated volume

  

- Price

 

Date 10/11/2017

1,200,000 @ 10pence

 

e)

 

Date of the transaction

 

10 November 2017

 

f)

 

Place of the transaction

 

Outside a trading venue

 

END

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Finlay Thomson, IR

 

Canaccord Genuity Limited (+44 (0)20 7 523 8000)

Henry Fitzgerald O'Connor / James Asensio

 

Panmure Gordon (UK) Limited (+44 (0)20 7 886 2500)

Adam James / Atholl Tweedie

Tom Salvesen

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg / Georgia Edmonds / Tom Huddart

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCURAURBRAAAAA
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.